Publication activity
Articles grouped by publication year
Hover over a year or focus the chart and use arrow keys to inspect values.
2026 is year to date. 0 undated publications excluded.
Research across participating journals · All insights follow your collection filters.
Publication activity alongside incoming citations.
Articles grouped by publication year
Hover over a year or focus the chart and use arrow keys to inspect values.
2026 is year to date. 0 undated publications excluded.
OpenAlex · year of the citing work
Hover over a year or focus the chart and use arrow keys to inspect values.
2017–2026 annual-history window. 2026 is year to date. Unknown years have gaps.
Leading affiliations and themes in this collection.
Full distributions & methodology ↓Independent sources. Clear time scales.
Crossref and OpenAlex · separate totals for the same publication cohorts
Hover over a year or focus the chart and use arrow keys to inspect values.
Latest lifetime totals, grouped by the cited article’s year. These are not citations received in that year.
OpenAlex · incoming citation links grouped by citing-work year
Hover over a year or focus the chart and use arrow keys to inspect values.
2017–2026 annual-history window. 2026 is year to date. Unknown years have gaps.
Select journals to compare the same collection filters. Source totals stay separate. These measures describe research activity, not journal quality.
Articles by publication year
Latest lifetime totals · grouped by publication year
Latest lifetime totals · grouped by publication year
By year of the citing work · 2017–2026
2026 is year to date. Crossref and OpenAlex lifetime charts share a citation scale. Unknown observations appear as gaps; known zero stays zero. Annual receipts use available OpenAlex histories and may not sum to lifetime totals. 0 undated publications excluded from publication-year charts.
Crossref citation coverage: 3 / 3 publications (100.0%). Latest observation: 21 Oct 2026, 07:22 UTC. Means and percentages use records with known counts.
DOI-matched OpenAlex observations for the same selected publications. These counts are separate from Crossref and are never added together.
Observation range: 21 Oct 2026 07:22 UTC — 21 Oct 2026 07:22 UTC. Missing matches are not zero citations. Previous observations may remain if a refresh fails or a DOI no longer matches.
OpenAlex affiliations and primary-topic classification. Each publication counts once per institution or country; multi-affiliated publications appear in multiple groups, so percentages can sum above 100%. Countries describe author affiliations, not nationality. Topics use one primary topic per publication.
3 / 3 with data · 0 missing or unmatched. Percentages use all 3 selected publications.
3 / 3 with data · 0 missing or unmatched. Percentages use all 3 selected publications.
3 / 3 with data · 0 missing or unmatched. Percentages use all 3 selected publications.
Citations are the latest recorded totals for articles published in each year, not citations received during that year. Crossref and OpenAlex remain separate and share the same citation scale. 2026 is incomplete; newer articles have had less time to receive citations.
0 undated publications excluded. Unknown citation counts are shown as —, never as zero. Partial coverage can understate totals; expand each table for known / total records.
| Publication year | Journal / scope | Publications | Publications | Crossref known | OpenAlex known |
|---|---|---|---|---|---|
| 2023 | All selected publications | 3 | 3 | 3/3 | 3/3 |
| Publication year | Journal / scope | Crossref citations | Publications | Crossref known | OpenAlex known |
|---|---|---|---|---|---|
| 2023 | All selected publications | 5 | 3 | 3/3 | 3/3 |
| Publication year | Journal / scope | OpenAlex citations | Publications | Crossref known | OpenAlex known |
|---|---|---|---|---|---|
| 2023 | All selected publications | 9 | 3 | 3/3 | 3/3 |
Incoming citations to the selected publications, grouped by the year of the citing work. This is separate from lifetime citation totals grouped by the cited article’s publication year.
The publication filters above define which articles receive the citations. The citation-year range below only controls this chart and the incoming-citation comparison. Removing publication-year filters includes older articles’ incoming citations too.
Annual history available for 3 / 3 selected publications. Supported display window: 2017–2026; 2026 is incomplete. Within a successfully fetched ten-year window, omitted years mean zero. Missing histories and years beyond a saved observation’s window remain unknown (—); partial coverage can understate totals.
Annual-history observations (UTC): 2026-10-21T07:22:46.751700+00:00 — 2026-10-21T07:22:52.631009+00:00. Older observations may be retained after failed or incomplete refreshes.
| Citation year | Journal / scope | OpenAlex · Citations received by year | Publications | Annual history known |
|---|---|---|---|---|
| 2017 | All selected publications | 0 | 3 | 3/3 |
| 2018 | All selected publications | 0 | 3 | 3/3 |
| 2019 | All selected publications | 0 | 3 | 3/3 |
| 2020 | All selected publications | 0 | 3 | 3/3 |
| 2021 | All selected publications | 0 | 3 | 3/3 |
| 2022 | All selected publications | 0 | 3 | 3/3 |
| 2023 | All selected publications | 2 | 3 | 3/3 |
| 2024 | All selected publications | 1 | 3 | 3/3 |
| 2025 | All selected publications | 3 | 3 | 3/3 |
| 2026 | All selected publications | 3 | 3 | 3/3 |
Counts represent citation links, not unique citing papers across a journal: one paper citing two selected articles contributes two links. Older citations outside this window are excluded, so annual sums need not equal lifetime totals. OpenAlex methodology ↗
Publications by publication year. 2026 is an incomplete year.
| Period | Publications |
|---|---|
| 2023 | 3 |
Latest Crossref totals for the selected publications; not citations received in the selected years.
Unknown counts are excluded from the mean, median and cited-publication rate.
Same filters, source and counting rules across journals. Descriptive statistics, not a quality ranking.
| Journal / publisher | Publications | Crossref citations | OpenAlex citations | OpenAlex coverage | Crossref mean | Crossref median | Crossref cited %* | Crossref coverage |
|---|---|---|---|---|---|---|---|---|
| International Journal of Research in Business and Social Science SSBFNET | 3 | 5 | 9 | 3/3 | 1.67 | 1 | 66.7 | 3/3 · 100.0% |
* Percentage among publications with a known citation count.
This research aimed to identify the key drivers of the pharmaceutical supply chain during the COVID-19 pandemic disruption, focusing on the South African pharmaceutical industry. The study aimed to unveil the dynamic strategies and challenges experienced during the pandemic and suggest recommendations for resilient supply chain operations. The study drew on established supply chain management theories and integrated them with the unique and novel circumstances of the COVID-19 pandemic. It mainly referred to theories regarding pricing, strategic sourcing, ICT usage, product availability, and logistics management contextualised within the pharmaceutical industry. An exploratory research approach was adopted to uncover the five overarching themes that function as pharmaceutical supply chain drivers during the COVID-19 pandemic. Semi-structured interviews were used to acquire the primary data with industry supply chain professionals, supplemented with secondary data from industry reports and relevant literature. The findings revealed that the pricing of medications, strategic sourcing decisions, information and communication technology, the availability of pharmaceutical products, and logistics management played critical roles in the pharmaceutical industry's supply chain during the COVID-19 pandemic. Disruptions caused by the COVID-19 pandemic led to challenges such as price hikes, supply shortages, and logistical complications. The study provides crucial insights into managing supply chain disruptions amid a global health crisis. Implementing dynamic pricing mechanisms, developing resilient sourcing strategies, using ICT effectively, improving inventory management, and enhancing logistics management are recommended for robust supply chain operations. The findings contribute to academia by enriching the existing body of knowledge and offering practical solutions for industry supply chain professionals. The research is original and timely, offering a unique perspective on the South African pharmaceutical industry's supply chain during an unprecedented global health crisis. The results are valuable for academia and industry, shedding light on the adaptive strategies, challenges encountered, and lessons learned from navigating the pharmaceutical supply chain during the COVID-19 pandemic.
The COVID-19 pandemic had a significant impact on the pharmaceutical industry, leading to severe interruptions in global medicine supplies. Both large and small businesses implemented exceptional strategic efforts to mitigate the impact of the infection and minimize the resultant financial harm. A total of twenty-five semi-structured interviews were carried out with pharmaceutical supply chain experts in South Africa in order to gain insight into the strategic reactions and long-term impacts of these responses, as perceived by the participants. The occurrence of strategic reactions seems to resemble those observed in prior instances of disruptions in the pharmaceutical supply chain, but with some degree of variation. These solutions encompass methods for addressing the specific supply chain disruption, managing the reality of supply chain disruption to efficiently handle low switching costs, and implementing attempts to recover by increasing the customer experience. These strategic initiatives were expected to lead to the permanent closure of numerous pharmaceutical enterprises, increased consolidation in the global pharmaceutical supply chain, and long-term changes in responsiveness and efficiency improvements.
This study analyzes the role of supply chain resilience in relationships supply chain risk management culture and firm performance during the disruption SME Batik clothing business in the Wedi sub-district, Klaten, Yogyakarta, Indonesia. This study is designed as a quantitative study with primary data obtained through the distribution of questionnaires. Purposive sampling was conducted, and a sample of 87 respondents was selected from SME Batik in Klaten, Yogyakarta that members of the batik SME cooperative. This study limits the sample to two positions: owner and manager. The data collected were analyzed using the structural equation model method using SmartPLS software. The results show that SCRM has a positive and significant effect on Firm Performance. This research also shows that SCRMC has a positive and significant effect on Re-engineering, Agility, and Collaboration. Testing the effect of mediating variables found the significant value of the influence of Re-engineering, agility, and collaboration in mediating the relationship between SCRMC (Supply chain management culture) and firm performance.
The COVID-19 pandemic had a significant impact on the pharmaceutical industry, leading to severe interruptions in global medicine supplies. Both large and small businesses implemented exceptional strategic efforts to mitigate the impact of the infection and minimize the resultant financial harm. A total of twenty-five semi-structured interviews were carried out with pharmaceutical supply chain experts in South Africa in order to gain insight into the strategic reactions and long-term impacts of these responses, as perceived by the participants. The occurrence of strategic reactions seems to resemble those observed in prior instances of disruptions in the pharmaceutical supply chain, but with some degree of variation. These solutions encompass methods for addressing the specific supply chain disruption, managing the reality of supply chain disruption to efficiently handle low switching costs, and implementing attempts to recover by increasing the customer experience. These strategic initiatives were expected to lead to the permanent closure of numerous pharmaceutical enterprises, increased consolidation in the global pharmaceutical supply chain, and long-term changes in responsiveness and efficiency improvements.
This research aimed to identify the key drivers of the pharmaceutical supply chain during the COVID-19 pandemic disruption, focusing on the South African pharmaceutical industry. The study aimed to unveil the dynamic strategies and challenges experienced during the pandemic and suggest recommendations for resilient supply chain operations. The study drew on established supply chain management theories and integrated them with the unique and novel circumstances of the COVID-19 pandemic. It mainly referred to theories regarding pricing, strategic sourcing, ICT usage, product availability, and logistics management contextualised within the pharmaceutical industry. An exploratory research approach was adopted to uncover the five overarching themes that function as pharmaceutical supply chain drivers during the COVID-19 pandemic. Semi-structured interviews were used to acquire the primary data with industry supply chain professionals, supplemented with secondary data from industry reports and relevant literature. The findings revealed that the pricing of medications, strategic sourcing decisions, information and communication technology, the availability of pharmaceutical products, and logistics management played critical roles in the pharmaceutical industry's supply chain during the COVID-19 pandemic. Disruptions caused by the COVID-19 pandemic led to challenges such as price hikes, supply shortages, and logistical complications. The study provides crucial insights into managing supply chain disruptions amid a global health crisis. Implementing dynamic pricing mechanisms, developing resilient sourcing strategies, using ICT effectively, improving inventory management, and enhancing logistics management are recommended for robust supply chain operations. The findings contribute to academia by enriching the existing body of knowledge and offering practical solutions for industry supply chain professionals. The research is original and timely, offering a unique perspective on the South African pharmaceutical industry's supply chain during an unprecedented global health crisis. The results are valuable for academia and industry, shedding light on the adaptive strategies, challenges encountered, and lessons learned from navigating the pharmaceutical supply chain during the COVID-19 pandemic.
This study analyzes the role of supply chain resilience in relationships supply chain risk management culture and firm performance during the disruption SME Batik clothing business in the Wedi sub-district, Klaten, Yogyakarta, Indonesia. This study is designed as a quantitative study with primary data obtained through the distribution of questionnaires. Purposive sampling was conducted, and a sample of 87 respondents was selected from SME Batik in Klaten, Yogyakarta that members of the batik SME cooperative. This study limits the sample to two positions: owner and manager. The data collected were analyzed using the structural equation model method using SmartPLS software. The results show that SCRM has a positive and significant effect on Firm Performance. This research also shows that SCRMC has a positive and significant effect on Re-engineering, Agility, and Collaboration. Testing the effect of mediating variables found the significant value of the influence of Re-engineering, agility, and collaboration in mediating the relationship between SCRMC (Supply chain management culture) and firm performance.
Source coverage refers to this result set; a publication may occur in several sources. Sync times refer to contributing journals.
Missing abstracts: 0 · Missing authors: 0 · Missing publication dates: 0 · Dates without day precision: 0
| Source | Most recent successful journal sync | Latest attempt |
|---|---|---|
| crossref | 21 Oct 2026 07:22 UTC · ijrbs | complete · ijrbs · 21 Oct 2026 07:22 UTC |
| ojs-rest | 21 Oct 2026 07:22 UTC · ijrbs | complete · ijrbs · 21 Oct 2026 06:46 UTC |
| oai-pmh | 20 Oct 2026 19:55 UTC · ijrbs | complete · ijrbs · 20 Oct 2026 19:50 UTC |
| openalex-enrichment | 21 Oct 2026 07:23 UTC · ijrbs | complete · ijrbs · 21 Oct 2026 07:22 UTC |